Growth factor versus mineral trioxide aggregate for treating mature permanent molars with irreversible pulpitis in children

Concerned Growth Factor Versus Miniral Trioide Aggregate in Management of Mature Permanent Molar of Children With Irreversible Pulpitis. An 18-month Randomized Control Trial

NA · Minia University · NCT07138287

This compares a growth factor treatment with mineral trioxide aggregate to see which better treats mature permanent molars in children who have irreversible pulpitis.

Quick facts

PhaseNA
Study typeInterventional
Enrollment200 (estimated)
Ages9 Years to 16 Years
SexAll
SponsorMinia University (other)
Locations1 site (Minya)
Trial IDNCT07138287 on ClinicalTrials.gov

What this trial studies

Children with a restorable mature permanent molar and a closed apex diagnosed with symptomatic irreversible pulpitis will receive either a concerned growth factor application or mineral trioxide aggregate applied to the affected tooth at Minia University Faculty of Dentistry. The interventions are intended to manage pulpal inflammation and preserve tooth vitality, though specific operative details were not provided. Eligible participants exclude medically compromised children, non-restorable teeth, and necrotic teeth. The study will monitor clinical outcomes such as symptom relief and tooth survival over follow-up, but exact endpoints and timing were not listed.

Who should consider this trial

Good fit: Children with a restorable mature permanent molar that has a closed apex and is diagnosed with irreversible pulpitis are the intended participants.

Not a fit: Medically compromised children, patients with non-restorable teeth, and teeth that are necrotic would not be expected to benefit from these interventions.

Why it matters

Potential benefit: If successful, the approach could preserve the infected tooth's vitality, reduce pain, and decrease the need for more invasive root canal procedures.

How similar studies have performed: Mineral trioxide aggregate is a well-established material with good evidence for pulp therapy, while growth-factor–based approaches are newer and have more limited pediatric data.

Eligibility criteria

Show full inclusion / exclusion criteria
Inclusion Criteria: Permanent Molar with closed Apex and diagnosed with irreversible pulpitis

\-

Exclusion Criteria:

* medically compromised children.

  * non restorable tooth
  * Necrotic tooth

Where this trial is running

Minya

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.

View on ClinicalTrials.gov →

Conditions: Concerned Growth Factor Versus Miniral Trioide Aggregate in Management of Mature Permanent Molar With Irreversible Pulpitis

Last reviewed 2026-05-15 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.